Biopharma staffers exhausted and susceptible to burnout
After years of litigation, Gilead and Teva's HIV antitrust trial kicks off in California
Digital health funding holds steady in Q1 after year of decline
Illumina, Icahn prepare for proxy showdown *please scroll down for all the latest news*
